# Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

> **NCT07410559** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 189 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Imlunestrant + abemaciclib
- **DRUG:** (dd)EC*4-T*4

## Key facts

- **NCT ID:** NCT07410559
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2029-04-01
- **Final completion:** 2031-07-01
- **Target enrollment:** 189 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07410559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07410559, "Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07410559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*